Epitracker aims to help people live longer and healthier. Our longevity program has resulted in discovery of approximately one hundred promising molecules, including our lead micronutrient, ETI-101, to protect cells against the aging process. ETI-101 is being advanced to market through an Epitracker spinout, Seraphina Therapeutics, Inc.
Promising molecules to expand longevity
Our longevity compound library includes molecules that may help to detect, prevent, and treat key conditions that impair our longevity and quality of life, including:
ETI-101 for anemia of inflammation
ETI-101 is a small molecule targeting both clinical diseases and anti-aging mechanisms.
Anemia of Inflammation
As we age, we are more likely to develop chronic, low-lying systemic inflammation and fragile red blood cells, which results in anemia of inflammation. Anemia of inflammation is the most common type of anemia in the elderly. An estimated 77% of people older than 85 years old have anemia of inflammation, which increases the risks of:
ETI-101 has demonstrated repeatable efficacy across multiple mammalian models. ETI-101 attenuated the following indices in models with disease:
- Alleviated anemia (raised hemoglobin, hematocrit, and RBCs)
- Lowered inflammation (lowered globulins, MCP-1, IL-6)
- Lowered liver iron deposition in animal model for NASH
- Reduced liver fibrosis severity in animal model for NASH
- Lowered cholesterol, triglycerides, glucose and insulin
ETI-101 Anti-Aging Mechanisms
Our studies to date support ETI-101's anti-aging mechanisms, including:
- Improved cell membrane integrity/resilience
- Improved mitochondrial function
- Upregulation of the AMP-activated protein kinase (AMPK) signaling pathway
- AMPK activation (phosphorylation)
- Predicted raised levels of geroprotective miRNA
ETI-101 Cell-Based Activity
In human cell-based systems mimicking a variety of disease states, ETI-101 has demonstrated significant dose-response anti-inflammatory and antifibrotic activity, including:
- Lowered MCP-1 (a pro-inflammatory chemokine)
- Lowered secreted immunoglobulin G
- Lowered Collagen I
- Lowered fibroblast proliferation
ETI-101 has a strong safety profile. To date, ETI-101 has demonstrated no cytotoxicity (using 12 human cell systems at four concentrations) and no off-target effects (using 78 functional assays at 10 concentrations).
ETI-035 and ETI-059 for cachexia
ETI-035 and ETI-059 are being developed to treat aging-associated weakness and wasting of the body (cachexia) due to severe illness, poor appetite and cognitive impairment. ETI-035 and ETI-059 are partial cannabanoid 1 receptor (CNR1) agonists that may help increase appetite and cognitive function in the elderly.
ETI-1023 and ETI-072 for inflammaging
ETI-1023 is an amino acid that is demonstrating anti-inflammatory and antiproliferative activity in human cell systems mimicking T cell-dependent B cell proliferation. ETI-1023 significantly reduced secreted interleukin (IL)-17F, a proinflammatory cytokine that increases with age and has been proposed as a key player in inflammaging. ETI-1023 is part of an untapped pathway with anti-aging potential.
ETI-072 is a phospholipid that demonstrating anti-inflammatory activity in human cell systems mimicking T cell-dependent B cell proliferation. ETI-072 significantly reduced secreted levels of multiple pro-inflammatory cytokines and chemokines, including interleukin (IL)-17F, IL-2, TNF-alpha, eotaxin-3, and MCP-1.